Affordable Access

deepdyve-link
Publisher Website

Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy.

Authors
  • Meka, Rakeshchandra R1, 2
  • Venkatesha, Shivaprasad H1, 2
  • Acharya, Bodhraj1, 2
  • Moudgil, Kamal D1, 2, 3
  • 1 Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, USA.
  • 2 Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • 3 Department of Medicine, Division of Rheumatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Type
Published Article
Journal
Nanomedicine
Publisher
Future Medicine
Publication Date
Jun 01, 2019
Volume
14
Issue
11
Pages
1455–1469
Identifiers
DOI: 10.2217/nnm-2018-0501
PMID: 30938236
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Aim: Rheumatoid arthritis is an autoimmune disease affecting the joints. Antiarthritic drugs are given systemically, thereby exposing various healthy organs to these drugs, resulting in adverse reactions. Accordingly, there is an urgent need for targeted drug delivery methods for inflamed joints. Materials & methods: We developed a liposomal drug delivery system using a novel peptide ligand (CKPFDRALC) named ART-2, which homes to the inflamed joints when injected intravenously to rats with adjuvant-induced arthritis. Results: The ART-2-coated liposomes encapsulating an antiarthritic drug, dexamethasone (DEX), were more effective in inhibiting arthritis progression than control-DEX liposomes or free DEX, despite a comparable safety profile. Conclusion: Peptide-targeted therapy has advantages over conventional drug delivery and can be adapted for rheumatoid arthritis therapy.

Report this publication

Statistics

Seen <100 times